NCT07215949 2026-02-23
Zilucoplan for Severe gMG Exacerbations
Ohio State University
Phase 3 Recruiting
Clinical Trials
11 trialsNCT06765161 2025-07-29
Efgartigimod in IVIG Dependent Myasthenia Gravis Patients
Clinique Neuro-Outaouais
Phase 3 Recruiting
NCT02950155 2024-10-26
Rinomax
Karolinska Institutet
Phase 3 Completed
NCT06587867 2024-09-19
Seronegative Myasthenia Gravis - Efgartigimod IV
University Health Network, Toronto
Phase 3 Recruiting
NCT05919407 2023-06-26
IMPACT-MG
Leiden University Medical Center
Phase 3 Unknown
NCT02774239 2023-02-21
SCIG-MG
University of Alberta
Phase 3 Completed
NCT05332587 2022-05-02
Efficacy and Safety of Low-dose Rituximab in the Treatment of Refractory Myasthenia Gravis
First Affiliated Hospital, Sun Yat-Sen University
Phase 3 Unknown
NCT01727193 2022-04-14
The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand Thymectomy
First Affiliated Hospital, Sun Yat-Sen University
Phase 3 Completed
NCT00995722 2017-06-02
EPITOME'
University of Miami
Phase 3 Terminated
NCT00294658 2017-05-23
Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy
University of Alabama at Birmingham
Phase 3 Completed
NCT00306033 2006-04-03
Intravenous Immune Globulin Treatment Compared to Placebo in Patients With Myasthenia Gravis
University Health Network, Toronto
Phase 3 Completed